Pharmacological inhibition of the ataxia telangiectasia and Rad3-related protein serine/threonine kinase (ATR; often known as FRAP-connected protein (FRP1)) has emerged for a promising tactic for cancer treatment that exploits synthetic lethal interactions with proteins involved with DNA destruction fix, overcomes resistance to other therapies and boosts antitumour immunity. A number https://damiena222nyi4.prublogger.com/profile